ovarian carcinosarcoma
ovarian carcinosarcoma
Explore linked clinical trials. Standard reference: MONDO:00037927 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Adnexal Diseases, Brenner tumor, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Urogenital Diseases, Urogenital Neoplasms, connective tissue neoplasm, endocrine system disorder, epithelial neoplasm, fallopian tube disorder, fallopian tube neoplasm, female reproductive system disorder, female reproductive system neoplasm, fibroepithelial neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian Brenner tumor, ovarian cancer, ovarian carcinosarcoma, ovarian clear cell cystadenocarcinoma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian mucinous cystadenocarcinoma, ovarian seromucinous carcinoma, ovarian serous cystadenocarcinoma, ovarian serous surface papillary adenocarcinoma, undifferentiated ovarian carcinoma | Active, not recruiting | Phase 2 | 2026-09-10 | NCT02101775 | |
| Recurrent Ovarian CarcinoSarcoma Anti-pd-1 Niraparib | ovarian carcinosarcoma | Recruiting | Phase 2 / Phase 3 | 2026-09-09 | NCT03651206 | |
| A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, Uterine Cervical Neoplasms, breast carcinoma, breast disorder, breast neoplasm, carcinosarcoma of the corpus uteri, cervix disorder, endocrine system disorder, endometrial carcinoma, endometrium neoplasm, female reproductive organ cancer, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian carcinosarcoma, ovarian disorder, skin disorder, triple-negative breast carcinoma, uterine disorder, vaginal cancer, vaginal disorder, vulva cancer, vulvar disease | Recruiting | Not applicable | 2026-08-10 | NCT07741968 | |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube carcinosarcoma, fallopian tube endometrioid adenocarcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinoma, ovarian carcinosarcoma, ovarian disorder | Recruiting | Phase 3 | 2026-08-07 | NCT06580314 | |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Bone Tissue, Neoplasms, Connective and Soft Tissue, Neoplasms, Fibrous Tissue, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, bone disorder, bone giant cell tumor, bone sarcoma, breast disorder, breast neoplasm, carcinoma, connective tissue neoplasm, dedifferentiated chondrosarcoma, endocrine system disorder, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, giant cell tumor, gonadal disorder, histiocytoma, malignancy in giant cell tumor of bone, malignant endocrine neoplasm, musculoskeletal system disorder, neoplasm, osteosarcoma, ovarian cancer, ovarian carcinosarcoma, ovarian disorder, poorly differentiated thyroid gland carcinoma, sarcoma, skin disorder, thyroid gland squamous cell carcinoma, thyroid gland undifferentiated (anaplastic) carcinoma, triple-negative breast carcinoma, undifferentiated high grade pleomorphic sarcoma of bone, undifferentiated pleomorphic sarcoma | Active, not recruiting | Phase 2 | 2026-05-22 | NCT03449108 | |
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion | Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, fallopian tube carcinosarcoma, fallopian tube clear cell adenocarcinoma, fallopian tube disorder, fallopian tube endometrioid adenocarcinoma, fallopian tube neoplasm, fallopian tube serous adenocarcinoma, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian carcinosarcoma, ovarian clear cell adenocarcinoma, ovarian disorder, ovarian endometrioid adenocarcinoma, ovarian serous adenocarcinoma, primary peritoneal serous adenocarcinoma | Recruiting | Phase 2 | 2026-03-23 | NCT04919629 | |
| A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer | Chromosomal Instability, Chromosome Aberrations, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Genomic Instability, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, Urogenital Diseases, Urogenital Neoplasms, breast disorder, breast neoplasm, carcinoma, endometrium neoplasm, epithelial neoplasm, female reproductive system disorder, female reproductive system neoplasm, head and neck squamous cell carcinoma, neoplasm, ovarian carcinosarcoma, skin disorder, squamous cell carcinoma, triple-negative breast carcinoma, uterine carcinosarcoma, uterine disorder | Recruiting | Phase 1 / Phase 2 | 2025-11-04 | NCT05902988 |